Steady improvement seen in data from open-label extension study Losmapimod, a drug that is currently in a Phase 3 clinical trial for FSH muscular dystrophy, continues to slow or stop… Read More »
Losmapimod continues to show promise
Epic Bio takes aim at DUX4
Leading-edge CRISPR biotech chooses FSHD as its first disease target Epic Bio, based in the San Francisco Bay Area, announced that FSHD is the first disease it plans to take… Read More »
Corinne Bronfman, October 28, 1947 – October 7, 2022
She leaves a legacy of remarkable progress toward treatments for FSHD The FSHD Society was deeply saddened to learn of the passing of Corinne Bronfman on October7, in Washington DC…. Read More »
Roche announces Phase 2 trial in FSHD
The drug, GYM329, aims to boost muscle growth Roche, the Swiss pharmaceutical giant, has announced that it is launching an international Phase 2 clinical trial for facioscapulohumeral muscular dystrophy (FSHD)…. Read More »
Sanofi and miRecule to partner on FSHD drug program
Bringing two technologies together for a best-in-class therapy miRecule, Inc., a biotech based in Gaithersburg, Maryland, today announced a strategic collaboration and exclusive license agreement with pharmaceutical giant Sanofi to… Read More »